Navigation Links
Aton Pharma Announces Distribution Partnership in Brazil
Date:5/12/2008

LAWRENCEVILLE, N.J., May 12 /PRNewswire/ -- Aton Pharma, Inc., a global specialty pharmaceutical company, announced today that it has signed a distribution agreement with Meizler Biopharma S/A to commercialize CUPRIMINE(R) and SYPRINE(R) in Brazil. Cuprimine is currently approved in Brazil, and Meizler is working to obtain regulatory approval of Syprine.

"Cuprimine and Syprine are medically essential products, and Aton is committed to making these products available wherever they are needed," said Michael G. Wells, Chief Executive Officer of Aton Pharma. "Brazil is the largest country in Latin America, and we are very pleased that we found Meizler to help us address the needs of patients in this country."

"Meizler has a long history of providing important medical therapies in Brazil," stated Avi Meizler, Meizler's President. "Cuprimine and Syprine both perfectly complement our current portfolio, and we look forward to helping Aton expand their presence in Brazil."

Meizler is a Brazilian Pharmaceutical company, headquartered in Sao Paulo, active in both the out-patient and hospital segments of the pharmaceutical industry. The company currently markets more than 40 products on the Brazilian market and has international partnerships in place with companies in the United States, Europe and Asia, to which Meizler provides various regulatory and commercial services. Using an advanced management and logistics system, Meizler is able to rapidly supply its high quality products to providers and patients. For more information, see http://www.meizler.com.br.

About Aton Pharma, Inc.

Aton Pharma, Inc., headquartered in Lawrenceville, NJ, is a global specialty pharmaceutical company providing essential treatments for under- treated diseases and rare illnesses around the world. Aton's mission is to improve patient outcomes and quality of life worldwide by enhancing and expanding access and availability of medically essential therapeutics. Aton's portfolio of seven products, with sales in over 30 countries, targets rare and orphan metabolic, neurological, cardiovascular and ophthalmic diseases. For more information, see http://www.atonrx.com.

CONTACT: Ed Stevens, 727-327-3396, Estevens3@tampabay.rr.com


'/>"/>
SOURCE Aton Pharma, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Pharmasset Selected to Join the NASDAQ Biotechnology Index
2. Tianyin Pharmaceutical to Present at the Brean Murray All-Cap All-China Conference in New York City on May 20, 2008 at 10:15 a.m. EDT
3. NuRx Pharmaceuticals Announces Change of Ticker Symbol to NUXP, Reverse Stock Split Now in Effect
4. Amylin Pharmaceuticals to Present at Baird Growth Stock Conference
5. Keryx Biopharmaceuticals, Inc. Announces First Quarter 2008 Financial Results
6. Celator(R) Pharmaceuticals Announces Appointment of Scott Jackson as CEO
7. EUSA Pharma Completes Acquisition Of Cytogen Corporation
8. Takeda Successfully Completes Tender Offer for Millennium Pharmaceuticals, Inc. and Announces Subsequent Offering Period
9. Arena Pharmaceuticals to Present at the Bank of America 2008 Healthcare Conference
10. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on First Quarter 2008 Financial Results on Monday, May 12, at 8:30 A.M. EDT
11. Onyx Pharmaceuticals to Present at Bank of America Health Care Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/26/2016)... ... May 26, 2016 , ... After several promising treatments ... at the City of Knowledge in Panama, a 6 year-old Duchenne’s muscular dystrophy ... earlier this year following FDA approval of a second application for a single ...
(Date:5/25/2016)... ... May 25, 2016 , ... ... delegation at BIO 2016 in San Francisco. Located at booth number 7301, representatives ... to answer questions and discuss the Thai biotechnology and life sciences sector. ...
(Date:5/25/2016)... ... May 25, 2016 , ... Scientists at the University of ... tried for mesothelioma may be hampering the research that could lead to one good ... here to read it now. , The team evaluated 98 mesothelioma patients ...
(Date:5/24/2016)... , ... May 24, 2016 , ... ... diabetes, and traumatic injuries, will be accelerated by research at Worcester Polytechnic Institute ... engines of wound healing and tissue regeneration. , The novel method, developed by ...
Breaking Biology Technology:
(Date:4/13/2016)... , April 13, 2016  IMPOWER physicians supporting Medicaid ... setting a new clinical standard in telehealth thanks to ... leveraging the higi platform, IMPOWER patients can routinely track ... and body mass index, and, when they opt in, ... convenient visit to a local retail location at no ...
(Date:3/31/2016)... PROVIDENCE, R.I. , March 31, 2016  Genomics ... leadership of founding CEO, Barrett Bready , M.D., ... addition, members of the original technical leadership team, including ... Vice President of Product Development, Steve Nurnberg and Vice ... have returned to the company. Dr. Bready ...
(Date:3/23/2016)... 23, 2016 ... Gesichts- und Stimmerkennung mit Passwörtern     ... MESG ), ein führender Anbieter digitaler ... mit SpeechPro zusammenarbeitet, um erstmals dessen Biometrietechnologie ... die Möglichkeit angeboten, im Rahmen mobiler Apps ...
Breaking Biology News(10 mins):